Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $162.00 at Robert W. Baird

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target upped by Robert W. Baird from $154.00 to $162.00 in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has an outperform rating on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Piper Sandler dropped their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Finally, Royal Bank of Canada increased their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $175.53.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $117.59 on Monday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market cap of $7.11 billion, a P/E ratio of 16.56, a P/E/G ratio of 1.02 and a beta of 0.57. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $134.17. The stock’s 50 day simple moving average is $112.22 and its 200 day simple moving average is $110.35.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock worth $720,160 in the last quarter. 4.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Coldstream Capital Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after purchasing an additional 165 shares in the last quarter. MidWestOne Financial Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 5.4% during the 3rd quarter. MidWestOne Financial Group Inc. now owns 22,063 shares of the specialty pharmaceutical company’s stock worth $2,458,000 after purchasing an additional 1,134 shares in the last quarter. Barclays PLC grew its holdings in shares of Jazz Pharmaceuticals by 19.1% during the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock worth $4,369,000 after purchasing an additional 6,289 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $2,491,000. Finally, XTX Topco Ltd lifted its position in shares of Jazz Pharmaceuticals by 57.5% during the 3rd quarter. XTX Topco Ltd now owns 11,631 shares of the specialty pharmaceutical company’s stock worth $1,296,000 after buying an additional 4,245 shares during the period. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.